Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

NCT01634763 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Interventions

DRUG: LDK378

Sponsor

Novartis Pharmaceuticals